The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: T-NK Cell Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.
Detailed description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.
Primary outcome measures
- Standardized uptake value (SUV) [Time frame: Baseline and 7-10 days after treatment]
Secondary outcome measures (2)
- Progress free suivival [Time frame: 3 years]
- Overall survival [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- Age > 18 years, regardless of gender.
- Histopathologically confirmed diagnosis of T-NK cell lymphoma.
- Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
- Availability of complete clinicopathological and follow-up data.
- Signed and dated informed consent form.
Exclusion criteria
- Patients who have previously received anti-tumor therapy.
- Patients with a history of other malignancies.
- Incomplete clinical information or imaging data.
- Concurrent other malignant tumors.
- Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
- Poor compliance.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
China · 1 center
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School, Shanghai — Shanghai
Identifiers
NCT: NCT06863441 · RuijinH 2025-34